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Abstract
For rare diseases that start early and are slowly degenerative, despite the 
desire to create solutions that benefit the patient, healthcare system realities can 
be prohibitive to generate an affordable and effective solution. The optimal care 
pathway for muscular dystrophy, similar to all degenerative diseases, would be a 
rapid and accurate diagnosis, pathophysiological confirmation and application of 
therapeutics that slowly replaces damaged tissue with healthy tissue, supported by 
adjuvant solutions that stimulate the tissue to repair and reduce inflammation and 
fibrosis. This would increase the lifespan and quality of life in an affordable way. For 
all diseases, two key stakeholders, the paying entity and the patient, fundamentally 
define whether revenue can be generated. Healthcare decision-making commission-
ers who agree to pay for the product and patient-reported outcomes jointly inform 
whether the intervention increases the quality of life related to existing standards 
of care and, therefore, if it should be paid for. This chapter explains why this has 
not yet happened and efforts initiated to correct this and addresses how the compo-
nents and data used in this decision-making process could be updated, adapted and 
integrated into every stage of the development of solutions and how organisational 
innovation may enable the field.
Keywords: HTA, PRO, evidence generation, innovation valuation, healthcare 
solution development
1. Introduction
Only around 5% of the 7000 identified rare diseases have an effective treatment 
and this is echoed in neuromuscular conditions [1]. Recent years have witnessed 
a number of cancelled developments of therapeutic interventions for muscular 
dystrophies that were at advanced stages of development, while other interventions 
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have been denied market authorisation, both in the US and Europe due to a lack 
of clinical efficacy. This means it is even more important to convince payers of the 
value for money of the few treatments that make it to market.
Obtaining market authorisation does not guarantee that payers will reimburse the 
product, that is pay for it, as growing concerns regarding the growing gap between 
the demand for health services and technologies and the available resources have 
increasingly introduced systems to assess the value for money of those products 
coming to market. The predominant processes for these value assessments are called 
health technology assessments (HTAs). Since the introduction of the National 
Institute for Health and Care Excellence (NICE) in 1999 in England, HTAs have 
spread throughout the world and now nearly every country has HTA organisations in 
place to help payers determine the value for money of new healthcare technologies.
These value assessments conducted by these HTA organisations consist of com-
piling, analysing, assessing and appraising the evidence available to show whether 
the health and economic benefits of a product compared to the standard of care (in 
the jurisdiction in question) are sufficient to justify the price, above and beyond the 
requirements of regulatory authorities.
There remains a lack of understanding and implementation of these consid-
erations in clinical development without which companies will struggle to gain 
reimbursement.
Negative reimbursement decisions by payers hinder access to the drug sub-
stantially, if not completely. Delays in reimbursement decision-making can lead to 
substantial delays in a new product gaining market access. Both delays and negative 
decisions impact adversely on sales and consequently return of investment (ROI). 
Furthermore, where the evidence presented to reimbursement decision-makers 
bears too much uncertainty it is highly likely that the accepted price will be far 
below the one required by the manufacturer. Thus, investing in better data collec-
tion can support reimbursement at an acceptable price.
Given the central role played by clinical trials in generating the evidence 
required for HTAs, everyone involved in designing clinical trial programmes and 
evidence generation needs to be aware of the methods and procedures required to 
generate the evidence required for HTAs above and beyond the evidence require-
ments for regulatory approval.
This is critical for developing solutions for rare diseases, such as the muscular 
dystrophies, due, fundamentally, to the low number of patients, and the significant 
variation of disease progression and severity among the patients that makes the 
generation of authority stipulated convincing statistical evidence significantly more 
complicated [2]. There are still many treatments in late stages of clinical validation 
(phase II and III) and more in earlier stages of development [3] targeting as many 
different aspects of this multi-faceted disease as possible.
In this chapter, we present a framework for what to consider during the design 
of clinical trials and evidence generation alongside and beyond clinical trials for 
muscular dystrophies to address the evidence requirements to gain reimbursement 
by payers.
Concerns regarding the growing gap between demand for health services and 
technologies and available resources have long created the need to regulate healthcare 
expenditure and governments have increasingly introduced formal systems to assess 
the value or money of healthcare technologies coming to market [4]. Nearly every 
country has formal reimbursement authorities in place to help payers determine 
whether a health technology is worth paying for. Value assessments conducted by 
these authorities consist of compiling and analysing the evidence to show the health 
and economic benefits of a product compared to the standard of care are sufficient to 
justify the price desired beyond the requirements of the regulatory authorities [4].
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Delays in reimbursement decision-making can lead to substantial delays in a 
new product gaining market access and negative reimbursement decisions by payers 
hinder market access substantially and thus impact adversely on sales and return on 
investment. Furthermore, where the evidence presented to reimbursement deci-
sion-makers bears too much uncertainty it is highly likely that the accepted price 
will be far below the one desired by the company. Thus, investing in better data can 
support reimbursement at a desired price.
Given the central role played by clinical trials in generating evidence for use in 
reimbursement assessments, those involved in designing clinical trials need to be 
aware of the evidence requirements of payers and reimbursement authorities. These 
differ and go beyond those of regulatory authorities.
We also explore the specifics of these issues and suggest actions that can be taken 
from conceptual design throughout the development of interventions that can 
help manufacturers unlock market access for their products. While all of the above 
applies to all pharmaceuticals, it is even more important in the context of muscular 
dystrophies and other rare disorders where data can only be generated in a small 
number of people as compared to more common conditions such as type 2 diabetes.
2.  The patient care pathway and standard of care for the muscular 
dystrophies
From either a patient care and management procedure or a healthcare solution 
development perspective, in an ideal scenario three components are needed:
• An established and clearly defined pathophysiological assessment of the 
development of the disease that enables an accurate prognosis at any time point 
in the disease progression that a standardised diagnosis confirms;
• An overlapping and reimbursement agency-approved care pathway that 
defines what needs to be done at every point throughout the disease; and
• A list of the standards of care that are purchased and used throughout the care 
pathway.
These three components can be further complemented by population health 
dynamics that also integrates environmental and socio-economic components 
linked to patient groups that further refine best approaches.
For highly prevalent diseases, the large number of patients that are affected 
generates a large source of data from which statistically relevant conclusions can 
be drawn that inform the points above enabling healthcare practitioners to make 
optimised patient care decisions, while innovators can look at the pathway to iden-
tify ‘pain points’ for which a specific product can be created to generate a solution. 
For conditions such as many forms of cancer or cardiovascular diseases, this has 
been further augmented as global patient data collections have become integrated, 
thereby generating even more specific and highly tailored approaches.
Rare diseases do not and have never had the same broad evidence base as the 
highly prevalent diseases and that has been recognised by the key stakeholders 
including regulatory authorities and governments who have introduced incentives 
to encourage the development of new treatments for rare diseases. These stakehold-
ers have globally networked and generated information and data resources such as 
the global academic network Treat NMD group (https://treat-nmd.org) focusing on 
all neuromuscular diseases to create a critical mass, ecosystem and hub of expertise.
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Duchenne muscular dystrophy is a serious genetic disease which is life-threat-
ening and shortens the patient’s life substantially. DMD is an X-linked disorder 
caused by mutations in the dystrophin gene and it is the most frequent muscular 
dystrophy in boys affecting 1 in 3500 live births [5, 6] and 1 in 50 million girls [7]. 
DMD is usually diagnosed before the age of 6. The disease causes progressive and 
unyielding muscle weakness frequently identified in the early toddler years when 
the child begins to miss development motor milestones [8, 9]. Loss of ambulation 
occurs generally around the age of 12. Only a few DMD patients survive beyond the 
third decade; most die because of respiratory complications or heart failure due to 
cardiomyopathy [10–13].
From a clinical care perspective in DMD, because clinical care recommenda-
tions did not previously exist, the US Center for Disease control (CDC) established 
the DMD Care Considerations Working Group, who in 2010 published the first 
comprehensive DMD care considerations [12]. These were revisited and updated in 
2018 to provide a complete care programme that addressed 11 key topics that occur 
in DMD, divided into five stages of disease [13–15]. The five recognised stages are 
diagnosis, early ambulatory, late ambulatory, early non-ambulatory and late non-
ambulatory, and the 11 key topics include neuromuscular, rehabilitative, endocrine, 
gastrointestinal/nutritional, respiratory, cardiac, bone health, orthopaedic, psy-
chosocial and transitions management. Within these publications the precise list 
of tests and actions that should be performed for these 11 topics at each stage are 
indicated. These initiatives have generated enormous amounts of benefit as proven 
by increased lifespans of patients and, critically, a drive to obtain even more detail 
about all the different characteristics of the disease and its precise progression [12, 
16–19]. This has included a push to reintroduce newborn screening tools and a 
larger effort to understand the pathology at the earliest times of the disease, which 
has recently been approved by the FDA [20].
The widely held and logical argument is that the sooner the intervention is 
started, typically in the young child, the greater the possibility that quality of life, 
morbidity and length of life can be enhanced.
As the prelude to this chapter, we have analysed the approved patient care and 
management pathways and integrated more recent published reports on early 
stage assessments and longitudinal monitoring, incorporated in as much insight as 
possible from the most current knowledge to create a best ‘what we know’ about 
the progression of muscular dystrophies, with a bias towards Duchenne muscular 
dystrophy (DMD). This has been done on the basis that by analysing one muscular 
disease as comprehensively as possible it will complement insights from our peers 
for the additional muscular dystrophies.
All muscular dystrophies are genetic; DMD is X-linked and can be an inherited 
mutation, a spontaneous mutation or due to germline mosaicism. The onset of 
DMD is illustrated by a list of manifestations that serve as ‘possible indicators’ of 
the disease that then precipitates a diagnostic assessment pathway that confirms or 
refutes the evaluation [13].
As demonstrated in the Norwegian paediatric DMD population, if there is a 
family history of muscular dystrophy, then this can mean that a confirmed diagno-
sis is possible almost immediately (mean age at diagnosis 2.8 years with a standard 
deviation of 3.2 years) [21] if there is not; then indicators such as speech delay, high 
Creatinine Kinase or transaminases, abnormal gait or delayed motor development 
followed by more specific genetic tests are used to confirm diagnosis that may not 
occur until the child is between 3 and 6 years of age. Newborn screening for high 
CK is a good predictor of DMD.
Why is this important? Until recently, understanding of muscular dystrophy 
during the neonate phase was very limited and it was speculated that there was 
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a ‘honeymoon period’ during which the disease did not develop significantly. 
Following the creation of the Bayley III child development assessment tool, 
the MDA-DMD clinical research assessed 24 children with ages ranging from 
0.37 months to 2.99 years [9]. The Bayley III tool assesses children in five devel-
opmental domains: cognition, language, social–emotional, motor and adaptive 
behaviour. It exists in tailored forms for specific diseases. For all patients, their 
language and cognitive skills were lower than healthy patients, as were their fine 
motor skills, while the gross motor skills were more significantly impacted, imply-
ing that the large muscle groups and the core muscle groups are being affected in 
these patients at an early age, and it was observed that these skills declined with age. 
In a 1-year follow-up, declining motor function continued to be observed [22]. This 
work was further confirmed in a larger study involving 114 patients in which delays 
in gross motor development were observed [23]. Similarly in the 4D-DMD study 
performed comparing the healthcare records and questionnaires of 76 patients with 
DMD compared to 19,000 patients from the general population revealed impaired 
gross motor development, with first signs visible at 2–3 months of age and more 
evident by 24 months of age [24].
Additionally there is early fibrosis in the newborn, and the possibility there may 
be a cardiac involvement without overt clinical signs [25], whether there are endo-
crinological or respiratory issues early in development is still unclear [26]. Given 
the gross motor involvement, it is possible that the diaphragm maybe affected, but 
no respiratory analyses in very young children have been reported. The diaphragm 
and abdominal muscles work in tandem to stabilise the spine and trunk and enable 
voluntary limb movement [27].
The standard of care is to start steroid treatment and physiotherapy from the 
age of 3 or 4, cardiac monitoring and spirometry, measuring pulmonary function 
and vital capacity, from the age of 6 [13–15] and it is known that from the age of 
6 onwards there is respiratory decline peaking at around 14 years of age, with a 
forced vital capacity (FVC) of 1 L [28] while a healthy child typically has a FVC of 
over 3 L. Those patients with a strong FVC have been reported to live longer [29], so 
we can speculate based on the outcomes from the Bayley III analysis if respiratory 
assessment or diaphragm thickness analysis may also be worthwhile measures at 
early stages of disease that can be assessed more frequently in the family practice 
setting, providing the equipment is available and correctly maintained [30].
How to approach this from a rehabilitative approach, especially in the neonate, 
given their developmental and overall regenerative capacity could be avenues to 
explore experimentally in animal models. It is recommended that excessive and 
high-impact exercise should be avoided in these patients due to the induction of 
muscle damage, without the normal muscle repair mechanism, thereby augmenting 
inflammation and fibrosis [31]. However if there is specific muscle involvement 
enabling a localised application of regenerative approaches combined with occu-
pational therapy or low-intensity rehabilitation, this may provide a foundation to 
prevent core muscle decline, and enable other therapies to be sequentially applied. 
Experimentally, this has been demonstrated in traumatic muscle damage [32, 33], 
while in Sarcopenia low-intensity electrical stimulation has demonstrated benefits 
[34, 35]. Whether these approaches can be innovated and combined, while address-
ing the genetic aspect is an open question; however, as shown for traumatic spinal 
cord injuries, combination approaches can offer benefit [36].
What happens next, generally to the patient is well documented and increas-
ingly being reported linked to the type of mutation that the patient has (nonsense, 
frameshift, splicing site, pseudoexon or missense). Using North Star Ambulatory 
Assessment (NSAA) as the outcome assessment, mild increases are observed 
in functionality very early and then from the age of 3 to 6.5 years the patient’s 
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ambulatory capacity increases [16] but it never reaches the age standardised healthy 
norm. Physical support maybe needed from the age of 8, and between the ages of 10 
and 12 most patients no longer have the ability to walk, which also leads to ortho-
paedic-related issues (contractures in the ankles and scoliosis in 90% of patients) 
with associated impacts on cardiovascular and pulmonary function.
It is important to look at the specifics of each patient because of the patient 
variability (genetic type and likely population health-related compounding factors) 
and the 11 topics that are considered essential in patient care and management, as 
demonstrated by the studies of Phillips and Brogna [29, 37]. Despite mean assess-
ments based upon Spirometry or 6MWT that indicate downward decline, at the 
individual patient level while eventually each patient’s condition deteriorates, the 
variation between the genetic mutation (whether it is an early or late deletion, 
a duplication or premature stop codon) related to functionality or lung capacity 
indicates that there are additional compounding factors that influence pathology 
progression.
One trend does seem to be clear and that is when a patient’s condition does 
deteriorate, it happens rapidly, in less than 12 months. This would suggest that a 
higher frequency of testing may be needed, which would for most families pres-
ent a logistical problem. Therefore, patient management solutions that can be 
implemented either virtually as that performed in standard cardiac monitoring or 
in family care practices may offer innovative interim patient care and management 
alternatives.
Considering that every patient is typically monitored via a dedicated special-
ist centre, who without question perform as many of the recommended tests as 
possible, because no correlation has been reported between disease progression at 
the biometrics being assessed, there may be external factors influencing disease 
progression. This is not a strange phenomenon, in the instance of asthma, increased 
incidences of asthma are reported in lower income families, because in many cases 
the houses can be either mouldy or damp resulting in spores entering the child’s 
lungs and inducing the disease [38]. It may therefore be worthwhile to integrate 
Population Health specialists into the ecosystem to provide additional insights, 
which may not generate an intervention, but will define an optimised and imple-
mentable care pathway that integrates for as many patient-specific non-disease 
specific variables as possible that can include broad social, socio-economic, envi-
ronmental conditions as well as healthcare policies.
The cumulative outcome will hopefully be not only a globally standardised care 
pathway for all patients with muscular dystrophy, but also the creation of interven-
tion and diagnostic innovations that will address reimbursement agencies’ require-
ments and standards.
3. The evolution of reimbursement decision-making
Concerns regarding the growing gap between demand for health services 
and technologies and available resources have long created the need to regulate 
healthcare expenditure and governments have increasingly introduced formal 
systems to assess the value for money of healthcare technologies coming to mar-
ket [4]. The predominant processes to do so are health technology assessments 
(HTAs) (ref).
The introduction of the National Institute for Health and Care Excellence 
(NICE) in 1999 in England significantly contributed to the globalisation of HTAs 
[39]. Nearly every country now has an HTA organisation in place to help payers 
determine the value of new medical interventions (Figure 1) [40].
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Historically, HTAs were performed after regulatory marketing authorisation had 
been granted. Due to the resulting gap between marketing authorisation and reim-
bursement, HTAs tend now to start much earlier—often in parallel with regulatory 
approval processes.
While there are differences between countries regarding defining the value 
of a new health technology, certain central requirements are common and can 
be addressed in clinical trials and evidence generation alongside and beyond 
clinical trials.
HTA is constantly evolving—the methods and processes as well the countries 
using it. Therefore, manufacturers developing healthcare technologies need to fol-
low and engage with HTA developments either directly or through the use of expert 
consultants.
4. HTA vs regulatory requirements
Regulatory authorities around the world require manufacturers to demonstrate 
the risks vs. benefits and quality based on clinical and non-clinical information. 
Reimbursement authorities require companies to demonstrate the comparative 
value of their product vs. the standard of care used in their jurisdiction. To do this, 
they appraise a new health technology or indication in comparing a set of product 
attributes relating to its efficacy, safety, impact on quality of life (QoL) and func-
tional status and pricing compared to the current standard of care.
Evidence used in HTAs for assessing the relative clinical and cost-effectiveness 
of new pharmaceuticals comes from a variety of sources, such as systematic litera-
ture reviews, indirect treatment comparisons and economic modelling. However, 
clinical trials conducted during the drug development process provide the most 
important source of treatment effect data for HTAs.
In recent years, some regulators including the EMA and FDA have taken steps 
to enable faster access to some drugs for rare conditions. For example, grant con-
ditional authorisation to treatments such as Ataluren for DMD. This is not without 
controversy and HTA authorities have expressed concern that there may be insuf-
ficient evidence available for them to determine the effectiveness and value of such 
treatments.
Figure 1. 
Countries with formal HTA systems worldwide.
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5. Common HTA data needs
Traditionally, most medicines received marketing authorisation after comple-
tion of large phase III clinical trials. Increasingly, medicines, especially such with 
novel or breakthrough status, are receiving regulatory approval based on much 
smaller phase II trials and/or non-comparative ‘single arm’ trials.
Therefore, it is important to consider the specific evidence requirements for 
HTAs (i.e. core of relative clinical and cost-effectiveness evidence) much earlier in 
clinical development programmes, that is, when designing phase II trials as well as 
when designing phase III trials.
Pharmaceutical companies need to consider five critical areas when designing 
clinical trials to be HTA ready as well as ready for regulatory authorities:
i. Choice of comparator
ii. Measurement of clinical effectiveness
iii. Quality of life (QoL) and patient reported outcomes
iv. The collection of resource use data
v. Follow-up time of the trial
5.1 Choice of comparator
Non-comparative/single arm trials create issues when HTA decision-makers try 
to compare the new technology vs. the standard of care. Placebo-controlled trials 
result in similar issues, if the placebo arm of the trial differs substantially from 
clinical practice. Both result in the need of extensive indirect treatment compari-
sons (ITCs), thus weakening the relevance and robustness of the clinical evidence 
in HTAs.
We recommend, wherever possible, to use the standard of care as the compara-
tor. This may be difficult where there is no gold standard and/or where clinical 
practice across and/or within countries involved in the trial varies. In such cases, 
we recommend consideration of the use of an active comparator based on physician 
choice to enable treatment comparisons relevant to HTA decision-makers in their 
respective jurisdictions.
5.2 Measurement of clinical effectiveness (efficacy and safety)
HTA requires outcomes to be patient relevant, and there is a growing inter-
est in the use of patient reported outcome measures (PROMs) in clinical trials 
[41–43]. In some disease areas, for example cancer, it may not be possible to power 
a trial to capture the treatment effect on hard outcomes, such as mortality/overall 
survival, and surrogate endpoints are used, such as progression free survival, 
which is an issue for ensuring the trial results are relevant to patient outcomes. 
However, surrogate endpoints can be useful when a clear and robust link can be 
established with patient relevant outcomes. For example, as for the link between 
HbA1c in type 2 diabetes and cardiovascular events. However, this is only when 
those links have been or can be validated by studies, so that HTA decision-makers 
can accept them.
We recommend, where possible, to select endpoints relevant to patient out-
comes (for example survival, PROMs—see more below). Where this is not possible, 
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we recommend establishing robust links between surrogate endpoints and patient 
outcomes and to validate them in separate studies or with external databases.
When considering the selection of endpoints for a clinical trial, it is also 
important to keep in mind how the data will be used in HTAs where the new 
technology will be compared with other technologies used in clinical practice via an 
ITC. Therefore, it is important to review which endpoints have been collected in tri-
als of most relevant comparator technologies to enable such treatment comparisons.
We recommend reviewing the endpoints used in previous trials, undertaking 
validation of these measures, whether the MCID is relevant and a predictor of 
patient outcomes and making a recommendation for consistent measures going 
forward to support comparisons between treatments.
However, there is non-alignment between the entities that provide market 
authorisation and those that perform HTAs. The FDA strongly recommends 
placebo-controlled trials [44], whereas the EMA suggests placebo in a two-way 
design study that enables a standard of care add on. With the caveat that if patients 
are being treated with corticosteroids, further patient stratification between the 
groups should be performed [45]. In both cases, a restoration of function or slowing 
decline is considered the main recommended endpoint, along with additional stud-
ies addressing activity levels, cardiac function and respiratory activity, while patient 
reported outcomes are suggested but not recommended.
Similarly, NICE in their evaluation of Idebenone, indicated that outcome 
measures to be considered could include pulmonary function, cardiac function, 
walking ability, motor function, muscle strength and HR-QOL, to assess the impact 
on quality of life [46].
This, however, is not reflected in the analysis of phase II and III clinical trials 
either performed or ongoing for muscular dystrophies. Of the 19 drugs tested in 
numerous phase III studies only 6 included PRO to enable a HR-QOL assessment, 
while of the 18 in phase II studies only 2 included PRO. One has to anticipate that 
because of the low number of patients in rare disease clinical trials and the impor-
tance of the impact of obtaining quality of life information to enable patients to 
have access to these medicines, PRO should become a standard in clinical studies, 
and that the PRO should be standardised throughout the field.
5.3 Quality of life (QoL) and patient reported outcomes (PROs)
HTA organisations use QoL and functional status data either for use in cost-
effectiveness evaluations or as individual value attributes of additional benefit a 
new technology offers. A separate economic model needs to be developed (typically 
in Excel) to utilise input data from the clinical studies and other sources.
To support the economic value case for a new pharmaceutical, the instruments 
used in the trial need to allow the generation of utilities (QALYs). For utility mea-
surement, data from generic health status measures, like the EQ-5D, tend to be 
preferred by HTA organisations.
For muscular dystrophies, PROs that inform changes in quality of life have been 
investigated to identify and tailor QoL since at least 2011 [47, 48]. The issue is that 
the consequences of the disease are broad and diverse, vary from patient to patient 
and change as a function of age. For the most juvenile patients, outcomes are depen-
dent on parent and physician reports due to a vocabulary limitation common to all 
young children. To some extent, this can be replaced with the overlapping Bayley III 
assessment, which can assess neonate responsiveness and functionality while simul-
taneously evaluating if the child has developmental differences [9]. Bayley III is not 
a QoL indicator per se, but in the context of neonate development, the comparison 
between healthy and DMD patients has revealed outcomes that would suggest 
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that this could be used for the earliest possible assessment. It is essential to read 
this publication for the indicated outcomes for functional expectation of healthy 
neonates and how this compares to patients with muscular dystrophy, because of 
the emphasis that regulatory bodies give to functional gains.
Following this, PROs are obtained routinely using the Paediatric Outcomes Data 
Collection Instrument (PODCI), SF-36 Health survey [41] and Neuromuscular 
module and Generic Core Scales of the PedsQL, which are also suggested by the 
EMA [45]. However, measuring QoL becomes significantly more complex as the 
patient grows. It has been reported that QoL outcomes using the PedsQL become 
unreliable as the patient ages [47], at least in the context of restoration of function, 
as defined by regulatory bodies versus increases in quality of life. The insinuation is 
that a restoration in function does not necessarily correlate to an increase in qual-
ity of life, which reinforces the concept that selected population health-related or 
additional pathophysiological measurements may need to be integrated into the 
appraisal as a third axis.
Additional research has been performed utilising the WHO ICF-CY [19, 49, 50], 
while the most comprehensive research on identifying, designing and optimising 
PRO specific for the muscular dystrophies has been reported from ScHARR [41–43] 
that forms a core part of the Project HERCULES initiative, a project led by the 
patient organisation Duchenne UK, aimed towards creating a suite of disease level 
HTA evidence including QoL assessment for DMD. The emphasis is that the QoL 
questionnaire needs to retain core expectations while also expanding the readouts 
as a function of neurological gain as the patient matures and can expand their 
expressiveness.
In muscular dystrophies, Project HERCULES (see below) is developing an 
optimised Duchenne muscular dystrophy (DMD)-specific instrument to create a 
preference-based measure to meet the needs of HTA.
Besides their use in cost-effectiveness evaluations, the use of generic and 
condition-specific instruments will generate data to inform HTA decision-makers’ 
assessments of the additional benefit of the new technology compared to the 
standard of care as individual value attributes.
QoL and functional status data should be collected at baseline and throughout 
the trial and follow-up period.
We recommend collecting QoL and functional status data using generic 
health status measures that allow the generation of utilities, as well as including a 
condition-specific instrument. In selecting which PROMs to choose, it is important 
to review the trials of the most relevant comparators to enable better comparison 
between technologies during HTAs.
5.4 The collection of resource use data
This includes hospitalisations, outpatient/GP appointments and tests/
investigations to inform the cost-effectiveness analysis. There is no universally 
recognised method for economic data collection in clinical trials and a variety of 
techniques are used. The methods and instruments used should reflect the health 
condition to new technology addresses. The researcher planning the trial should 
again review the trials of the most relevant comparators to identify potential 
methods and instruments.
Resource use data should be collected at baseline and throughout the trial and 
follow-up period. However, resource use data collection from a multinational 
clinical trial should be performed with caution due to the concerns over the gener-
alisability of the data for country-specific HTA submissions. Hence, there is a key 
role for local validation of resource use estimates from a trial and/or observational 
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data collection. Additional Burden of Illness studies should be undertaken alongside 
trials to show real-world evidence.
5.5 Follow-up time of the trial
Studies should have an appropriately long enough follow-up time to enable 
the collection of consistent, sufficient and robust data relevant to HTA decision-
makers. Minimising uncertainty about clinical effectiveness may be a particular 
challenge for life-long progressive conditions with limited data such as muscular 
dystrophies and there is no fixed time period favoured by HTA bodies.
In addition, a plan detailing how and when individual endpoints will be col-
lected is essential. This should include the frequency, methods, sources and time 
horizon within the data. Besides the data collection plan, the researcher planning 
the trial should also consider the development of a specific health economics/HTA 
statistical analyses plan (SAP) covering such aspects as to how PROM and resource 
use data will be analysed for HTA and use in economic models. This would comple-
ment the regular clinical study SAP.
6. HTA scientific advice
Some HTA bodies, for example NICE, offer HTA-specific scientific advice 
to developers of health technologies to help them develop evidence required for 
HTAs [51]. Also, the EMA and EUNetHTA (EU body responsible for co-ordinating 
HTA methods and policies in Europe) offer a joint scientific advice programme to 
companies with HTA organisations involved.
All of those processes come with varying requirements for preparation and com-
pany input and varying levels of opportunities for engagement with the involved 
parties.
7. Unofficial procedures
1. Advisory board meetings with health economists with clinical trial experience 
for selected key territories, HTA experts and clinicians to review and input into 
clinical trials.
2. One-to-one meetings with payer/HTA experts to review and gain input for 
clinical trial programmes from specific experts for specific regions and/or 
countries.
3. Working with specialist health economics consultants with clinical trial, HTA 
scientific advice and HTA experience to review plans, gain input into clinical 
trials, to develop whole HTA scientific advice programme tailored to the in-
dividual company requirements and to provide wider market access and HTA 
advice also supporting and/or conducting individual projects.
4. Patient and family input is crucial to fully understand the impact of the dis-
ease, on health, quality of life, socially and financially as well as any practical 
considerations relating to the feasibility of the trial design.
For all of the above, we recommend working with health economists with 
clinical trial and HTA experience to review plans, gain input into clinical trials, to 
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develop whole HTA scientific advice programme tailored to the individual company 
requirements and to provide wider market access and HTA advice also supporting 
and/or conducting individual projects. This can also include the consultants helping 
the company to navigate the official procedures.
8. Evidence generation alongside and beyond clinical trials
Beyond clinical evidence generation, developers of healthcare technologies need 
to develop a set of HTA value propositions covering the impact their technology 
will have on the unmet need, its comparative effectiveness demonstration (planned 
and expected and/or based on potentially available data), patient reported out-
comes (including quality of life), cost-effectiveness, and resource use, costs and 
budget impact as well as covering a PICO (Patient, Intervention, Comparator and 
Outcomes) statement.
Companies need to conduct early HTA-specific gap analyses and HTA feasibility 
assessments to identify gaps in their own as well as their comparator’s evidence base 
to allow for sufficient time to fill those through evidence generation within, along-
side and beyond clinical trials. With this, it is also important to remember that HTA 
preparations need to start early with HTA input into phase II clinical trial planning 
and designing at the very latest and from there on being a constant and equal (to 
regulatory) part of any development as getting reimbursement is equally important 
as getting a marketing authorisation.
9. Other considerations
Companies need to conduct early economic modelling and payer research to 
inform their pricing strategy reflecting their evidence base. Technologies that 
are too expensive and do not have a significant benefit over existing alternatives 
are unlikely to be approved. The key driver of cost in many economic evaluations 
submitted to HTA organisations is the price of the technology. Where the list price 
is too high for the technology to be approved for reimbursement, companies can 
provide discounts and/or other commercial arrangements to reduce the cost to an 
approvable level. There are also instances when a new technology may be additive 
to existing standards of care. Where this care is already expensive, it is possible for a 
new treatment to not be cost-effective even at zero cost [52].
In other instances, it is not the list price of the technology but the uncertainty of 
the submitted benefits driving the need for a discount and/or commercial arrange-
ment. In HTAs evidence uncertainty is critical and higher the uncertainty the lower 
the acceptable price will be. Therefore, investing in better data and filling evidence 
gaps as early as possible can support a better price and avoid the need for a discount 
and/or commercial requirement.
Economic modelling can help a company to identify the potential need for a 
discount or commercial arrangement and where they are required the potential 
magnitude required.
Beyond evidence generation and pricing, manufacturers should follow and 
engage with HTA developments, follow comparator HTAs to inform their own HTA 
preparations and be open, transparent, collaborative and realistic when engaging 
with HTA authorities.
Support is available to companies throughout the whole process from early 
development through to the conclusion of individual HTAs from official bodies, 
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like HTA organisations, as well as from experienced HTA expert consultants. 
Companies should make use of the support available to them.
Furthermore, stakeholders from different backgrounds involved in addressing 
challenges in healthcare are increasingly working together cross functionally and 
globally. Developers of treatments for muscular dystrophies should also consider 
such approaches where they are not already happening. One outstanding example 
of such a collaboration in muscular dystrophies is Project HERCULES [53, 54].
10. Project HERCULES
In the field of Duchenne muscular dystrophy (DMD), one of the most common 
and severe forms of muscular dystrophy, Duchenne UK set up Project HERCULES 
(HEalth Research Collaboration United in Leading Evidence Synthesis) to develop 
tools and evidence to support HTA for new treatments for DMD [53–55].
Many pharmaceutical companies are developing potential treatments for DMD 
and are working individually to develop their approach to HTA. The variety of 
methods in use and the difficulties of generating data can lead to delays in introduc-
ing new treatments and inconsistent decision-making.
Duchenne UK invited pharmaceutical companies with a DMD product in 
development to a training day in February 2017 to explore modelling and HTA in 
DMD. This led to the establishment of Project HERCULES, a collaborative global 
project bringing together patient organisations, clinicians, academics, nine active 
pharmaceutical companies, HTA agencies and other advisors.
Project HERCULES has generated a set of disease-level evidence and tools 
including a natural history model, burden of disease data, a de novo DMD-specific 
quality of life metric, and a core economic model. These individual workstreams 
have been developed in parallel through an iterative process enabling evidence 
generated for one work stream to inform the others. This iterative approach ensured 
that input from clinicians, patients and carers and other experts was used for 
multiple purposes minimising the demands on stakeholders.
The leadership of a patient organisation enabled access to data sources and 
expertise that may be inaccessible for individual or industry researchers. The 
patient organisation was also able to recruit patients and parents to participate 
in the research through the use of social media and offline networks. There have 
been clear efficiencies for manufacturers in being able to access evidence and 
expertise and a greatly reduced cost compared to developing these evidence and 
tools in isolation.
The collaborative approach taken by Project HERCULES was not without chal-
lenges. Researchers often needed to learn to explain complex concepts in accessible 
language to ensure patients and lay members could effectively contribute. Balancing 
the input from patients and families with clinical, industry and HTA experts has 
also been challenging. Project HERCULES selected researchers in part by their 
readiness to work collaboratively with stakeholders ensuring that they were work-
ing closely with the other research teams and actively listening and responding to 
all the information obtained, and not simply seeking confirmation for what they 
expected to find.
Despite the challenges, Project HERCULES has consistently taken a collaborative 
approach that has had a clear impact on each workstream:
• Enabling researchers to test assumptions against lived experience and develop 
their own understanding of the condition and care pathway
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• Identification of meaningful disease stages including the previously over-
looked transfer state between the traditional stages of late ambulatory and 
early non-ambulatory. Patient and parents told researchers about the impor-
tance of being able to weight bear for a period following the loss of ambulation. 
This state has been incorporated into the natural history model, which informs 
the other work streams.
• Development of a bespoke Quality of Life preference based measure that better 
reflects the lived experiences of those with DMD as well as the views of clini-
cians and other experts.
• An economic model that builds on the actual experience of clinicians, patients 
and families
• A burden of illness study focusing on what is most important to clinicians, 
patients and families.
11. Impact on investment and return on investment
In healthcare, and particularly therapeutic intervention, development takes a 
long time, typically over 14 years [56, 57], and is costly (up to $2.6 billion, [58]), 
which means that significant risk has to be carried for a long duration before know-
ing if the product was worth the investment. However, in the context of rare dis-
eases, the scenario is significantly different. Whereas the development up to launch 
of a medicine for a very common condition may cost $2.6 Billion, for the muscular 
dystrophies the value might be closer to $400 Million. The number of patients 
involved in the trials are significantly lower, the duration of the trials shorter and 
upon market release, an extensive sales force is not necessary, as patients are typi-
cally referred to centres of excellence [59–61], and clinicians who focus on treating 
patients with rare diseases are typically well versed in developments in the field, 
while patients associations perform stellar work in communicating with patients 
and their supporters what is happening [7, 62–68]. As explained above, achieving a 
marketing authorisation does not guarantee reimbursement that companies need to 
achieve before they can realise uptake and sales.
This leads us to two questions: (a) what impact integrating HTA requirements in 
clinical trial design has on investment decision-making, and (b) what impact it has 
on return on investment.
To answer the first question, we need to look at how pharmaceutical investment 
decisions are informed.
The decision to invest in the creation of a medical product, as for all other 
businesses, hinges on the definition of the market size, the terminal market value. 
The terminal market value is then reverse calculated to the potential present value 
by integrating in phase specific costs, risks and probabilities of success to give a 
net present value (NPV). If the NPV is positive, then the innovation is considered 
worthwhile to invest in, whereas if it is negative, the rule of thumb is to not invest.
NPV calculations are only as good as the data used to generate them, and both 
accurate and comprehensive values ideally should be used, based on real market 
dynamic, the latest clinical success rates and considering the latest reimburse-
ment approaches (such as HTAs). Thus, designing clinical trials that are more 
likely to result in better data and addressing HTA evidence requirements improve 
NPV calculations and thus optimise investment decision-making [69]. However, 
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it is important to state that there is the possibility that market authorisation agen-
cies and reimbursement bodies may not accept clinical data from other jurisdic-
tions due to different standards and regulations. Therefore, while NPV outputs 
are additive, the developer may need to assess if different clinical trials need to 
be performed in different locations and if and how the data can be used within 
a comprehensive evidence dossier that can be submitted to as many different 
agencies as possible.
The answer to the second question is that investing in better evidence genera-
tion will lead to higher chances of gaining desired reimbursement at the desired 
price, thus unlocking market access and sales potential early, thus having a positive 
impact on ROI. For the rare diseases, accounting for post-marketing surveillance, 
manufacturing and general admin costs, to reach a balance of zero, the product 
will need to generate at least $1 Billion in life time sales; to enable the innovators 
to sustain and expand their pipeline, generating additional new interventions 
for other rare diseases, life time sales between $2 Billion and $8 Billion would be 
required. Based on marketing authorisation restrictions on recently approved 
DMD interventions, that are based upon the differing forms of dystrophinopa-
thies, this revenue level would need to be generated from generating a beneficial 
effect (clinical effectiveness and cost effectiveness) for 10% of the muscular 
dystrophy population, who would likely need to administer the solution every year 
for the rest of their life, that could be an additional 25 years based on the increased 
standards of care. This combined information is then used to define the agreed 
price of the solution with the reimbursement agency, within the specifics of the 
healthcare system and marketplace in each different geography (this can be an 
entire country or a region within a country).
Governments have tried to be flexible to account for the market risks, policy 
changes have been implemented, such as the orphan drug definition in the 
EU. Because of the potentially low revenue potential, investing in solutions for 
rare diseases carries a higher risk, as costs cannot be recovered, therefore acts that 
provide market exclusivity for 12 years for paediatric diseases, in competition with 
‘similar competitive products’. Additionally, to facilitate R&D in healthcare, most 
countries offer R&D tax credits, independent of the source of the R&D funding, 
and using a very broad definition of what constitutes a R&D cost to stimulate such 
endeavours. These credits can be used to offset taxes on profit, providing the entity 
reinvests the revenue.
Conceptually for a paediatric rare disease, the rule may need to be revisited to 
reconsider what is the definition of a similar product to provide clarity to innova-
tors. Arguably it is any intervention that offers disease correction, which can be 
a very broad definition or is it based upon similar mechanisms of action; ideally 
innovators would need this point clarified to enable better clinical trial design. This 
is reflected in the clinical trials that are ongoing and appear to be following the 
conceptual design associated with major diseases, that is an ‘all or nothing’ response 
based upon the intervention being assessed.
Given that the disease takes years to manifest itself, and varies significantly from 
patient to patient as seen in other progressive degenerative diseases or traumatic inju-
ries with inconsistent and differing measurements, it is more likely that a spectrum 
of concepts and solutions need to be integrated together as function of the patient 
and the tissue damage at that specific stage within the complete disease progression 
to provide beneficial outcomes; this is likely going to include standard chemical 
entity interventions, anti-inflammatories and physiotherapy and potentially stem 
cells, biomaterials, genetic correction, tailored and designed as a comprehensive 
intervention solution tailored to the patient and their population health status.
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12. Conclusions
In summary, we would like to emphasise that for a product to be able to get a 
positive HTA recommendation leading to reimbursement by payers, manufacturers 
need to carefully consider the evidence needs of HTA authorities when planning 
clinical trials and evidence generation programmes.
For each new product, this should start early, that is when planning phase II tri-
als, and continue throughout the clinical development process in order to optimise 
the chances of gaining reimbursement and consequently return of investment.
Beyond evidence generation and pricing companies follow and engage with 
HTA developments, follow comparator HTAs to inform their own HTA prepara-
tions and be open, transparent, collaborative and realistic when engaging with HTA 
authorities.
Support is available to manufacturers throughout the whole process from early 
development through to the conclusion of individual HTAs from official bodies, 
like HTA organisations, as well as from experienced HTA expert consultants. 
Additionally, innovative initiatives, such as Project HERCULES, are existing to 
support developers but also serve as examples of what is possible and can be done 
beyond existing support structures and options. Manufacturers should make use of 
the support available to them.
Furthermore, addressing the evidence requirements of payers and HTA 
organisations in clinical trials and other evidence generation can lead to improved 
investment decision-making and have a positive impact on ROI.
It is also important to emphasise that developers of healthcare technologies 
need to address the evidence needs of reimbursement decision-makers early and 
throughout the development process in order to optimise their chances of gaining 
market access at a desired price unlocking ROI. To obtain and support this outcome, 
there may need to be a reconfiguration of the muscular dystrophy R&D ecosystem. 
A large amount of fundamental research has been and is still performed in the 
muscular dystrophies, mostly paid by charities such as MDA, Telethon, Duchenne 
and AFM, to name only a few. In no way does the volume of research and funding 
for muscular dystrophy compare to the major diseases.
For the major diseases, the years of highly funded fundamental research has 
resulted in outcomes that have translated to the clinic for the benefit of patients that 
is founded upon a significant amount of independently validated and reproduced 
data. Naturally, at the public funding level, policy is therefore biased towards 
encouraging fundamental research to have a translatable dimension to justify to the 
taxpayer the expense.
Rare disease researchers have not had a large knowledge resource but find them-
selves in the position that they need to accelerate their translatable research, due to 
patient need, without the same foundation of knowledge to rely upon. This is not 
going to change; however, different approaches to managing the knowledge that is 
generated from the limited financial support that is given to fundamental research 
in the muscular dystrophies would be beneficial for this field, other muscular 
diseases and the rare diseases field as a whole. But the barriers to progression are 
compounded by additional characteristics that are common to all other diseases and 
the culture of R&D and others that are unique to the field of muscular dystrophy.
One significant issue in knowledge generation in the muscular dystrophies is 
the genotypic diversity within each type that often prevents statistically relevant 
insights being obtained that can be leveraged into intervention development. This 
is because to obtain some level of relevant data the work has to be performed in 
an animal model that corresponds to the specific disease genotype. This means 
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creating the model (often a mouse) through transgenic modification, and after 
stabilising the model, assessing if the genotypic change generates a disease pheno-
type that corresponds to the human form of disease. On the proviso that a compre-
hensive understanding of the disease progression and phenotype is understood in 
the human.
Pre-clinical modelling is used to generate data that show a corrective effect, 
levels of toxicity, intervention metabolism and potential dosing. After generation of 
the comprehensive dossier for review, a positive ethical review board will then per-
mit a phase I testing of the drug in humans. The aim is to define if the considered 
therapeutic dose is toxic to a healthy human. If it is confirmed that the therapeutic 
does not harm a human, it is then approved to test in a small population of patients 
if in addition to not harming the patient it confers some level of corrective effect 
(phase IIa). If positive, the study can be expanded to more patients (phase IIb). 
Positive data from this phase enable the larger scale phase III, efficacy study on large 
patient populations. For diabetes and CVD, the available patient population for 
recruitment is huge.
For muscular dystrophies it is not; this means that a substantial amount of 
evidence has to be generated from between 30 to 250 patients, if they correspond 
to the inclusion/exclusion criteria of the trial, which typically includes not taking 
other experimental interventions. Independent of whether a disease is rare or 
frequent, this is not possible. It would be impossible and likely rejected by market 
authorisation bodies if this approach was taken for a highly prevalent disease 
as an evidence collection method. Policy changes have occurred focusing on 
rare diseases to be more flexible on effect and patient numbers, but clinical trial 
design still hinges on an ‘all or nothing’ therapeutic effect from a single interven-
tion. This does not correspond to the complexity of muscle tissue, the diversity 
between patients, the impact of comorbidities and the regenerative characteristics 
of muscle.
For fundamental researchers, specifically those in academia who perform most 
of the fundamental research operate in a ‘publish or perish’ professional environ-
ment. The nature of fundamental R&D is that >90% of the data generated, at first 
glance, is a negative result, and the space limitations in articles accepted for publica-
tion means that even very limited positive results are shown. A negative result being 
defined as an outcome that does not correspond to enabling a chosen question to be 
answered, it does not mean the data are useless or invaluable.
With such limited resources, financially, biologically and clinically, but with 
such a clear patient need, the field needs to reconsider how it best leverages its data, 
especially as there are not a high number of researchers active in muscular dystro-
phy, in comparison to cancer or cardiovascular diseases.
This could be resolved through a ‘research data’ database that can be accessed 
by all accredited researchers to enable searching other historical data from other 
sources to look for concepts that did not work to prevent wasteful repetition, or to 
look at the unpublished data with a new perspective to enable a different insight. 
This also needs to happen with clinical data, from those patients in trials to those 
having their disease history mapped, albeit with a greater ethical oversight. There 
are nearly 13,000 patients presently in global clinical trials for Limb Girdle, Beckers 
and Duchenne muscular dystrophy who will be generating what may first appear to 
be non-relevant data related to the defined outcomes, but it is very likely that in the 
context of age, disease progression, biometrics, comorbidity status, mental health 
status, population health characteristics as well as response to intervention, these 
data are going to massively inform the field and globally standardised clinical care 
pathways and patient biometric measurements.
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